BibbInstruments

BibbInstruments Gross Margin

The Gross Margin of BibbInstruments (BIBB.SL) as of Oct 20, 2026 is 16.21 %. In the previous year, Gross Margin was 62.50 % — a change of -74.06% (lower).

Gross Margin

16.21 %

YoY

-74.06%

Last updated:

Gross Margin of BibbInstruments is 2025 16.21 % . Gross Margin of BibbInstruments was 2024 62.50 % . It decreases by -74.06% lower compared to the previous year.

BibbInstruments's gross margin stands at 16.2%, down from 51.8% several years earlier.

The BibbInstruments Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2017
22.66 SEK
Jan 1, 2018
51.79 SEK
Jan 1, 2019
59.48 SEK
Jan 1, 2020
58.92 SEK
Jan 1, 2021
62.50 SEK
Jan 1, 2025
16.21 SEK
The BibbInstruments Gross Margin history
YEARGross MarginYoY
16.21 %-74.06%
62.50 %+6.07%
58.92 %-0.93%
59.48 %+14.85%
51.79 %+128.57%
22.66 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

BibbInstruments Stock analysis

What does BibbInstruments do? BiBBInstruments AB generates revenue through the development and sale of diagnostic instruments for early cancer detection, primarily utilizing its EndoDrill technology platform. The company markets specific products including EndoDrill GI Upper for stomach biopsies, EndoDrill GI Lower for intestinal biopsies, EndoDrill GI Lung for lung biopsies, EndoDrill Therapy for organ displacement procedures, EndoDrill Needle for breast biopsies, and EndoDrill Model X for multiple applications. These instruments are sold to hospitals with endoscopy specialist centers and surgical wards, focusing on Scandinavian countries as their primary market. The company's portfolio targets medical professionals requiring precise diagnostic tools for deep skin tissue analysis and treatment procedures. The business model centers on selling specialized biopsy instruments that enable early cancer diagnosis in various organs. EndoDrill GI Upper, GI Lower, and GI Lung are designed for gastrointestinal and respiratory tract biopsies, while EndoDrill Therapy facilitates treatment procedures involving stents and conductors. EndoDrill Needle specifically addresses breast biopsy needs, and EndoDrill Model X serves as an independent research project covering multiple anatomical areas. All products are distributed through hospital networks specializing in endoscopy and surgery. BiBBInstruments AB's revenue streams are derived from direct sales of its diagnostic instrument portfolio to healthcare institutions. The company focuses on Scandinavian countries for distribution, targeting hospitals with specialized endoscopy centers and surgical departments. The EndoDrill technology platform underpins all products, providing a unified approach to early cancer detection and treatment procedures across different medical specialties. BibbInstruments is one of the most popular companies on Eulerpool.

Frequently Asked Questions about BibbInstruments stock

Gross Margin of BibbInstruments is 16.21 % in 2025.

Gross Margin of BibbInstruments changed from 62.50 % to 16.21 %, representing a -74.06% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin BibbInstruments since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's BibbInstruments with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — BibbInstruments

All Key Metrics — BibbInstruments